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The lipid droplet (LD) is the major site of cholesterol
storage in macrophage foam cells and is a potential
therapeutic target for the treatment of atheroscle-
rosis. Cholesterol, stored as cholesteryl esters
(CEs), is liberated from this organelle and delivered
to cholesterol acceptors. The current paradigm attri-
butes all cytoplasmic CE hydrolysis to the action of
neutral CE hydrolases. Here, we demonstrate an
important role for lysosomes in LD CE hydrolysis in
cholesterol-loaded macrophages, in addition to
that mediated by neutral hydrolases. Furthermore,
we demonstrate that LDs are delivered to lysosomes
via autophagy, where lysosomal acid lipase (LAL)
acts to hydrolyze LD CE to generate free cholesterol
mainly for ABCA1-dependent efflux; this process is
specifically induced upon macrophage cholesterol
loading. We conclude that, in macrophage foam
cells, lysosomal hydrolysis contributes to the mobili-
zation of LD-associated cholesterol for reverse
cholesterol transport.
INTRODUCTION
Macrophage foam cells are a key component of atherosclerotic
lesions. Because enhancing cholesterol efflux from these cells is
an attractive means to reverse plaque lipid buildup, there has
been continued investigation on ways to promote net choles-
terol flux from peripheral tissues to the liver for excretion via
the bile, a process referred to as macrophage reverse choles-
terol transport (RCT) (Khera and Rader, 2010). The first step in
RCT is the release of cholesterol from lipid droplets (LDs).
Although classically defined as the cellular cholesterol ‘‘storage’’
organelle, current research highlights the dynamic nature of LDs
(Farese and Walther, 2009). LDs are comprised of a neutral lipid
core delineated by a phospholipid monolayer, which is coated
by proteins. Adipophilin is the macrophage LD coat protein,
and its levels are directly correlated to cellular neutral lipid
content and, recently, to atherosclerosis (Paul et al., 2008). ItCis important to understand how cholesteryl esters (CEs) in LDs
are hydrolyzed and mobilized for efflux, given that cytoplasmic
CE hydrolysis is increasingly becoming recognized as the rate-
limiting step for cholesterol efflux and whole-body RCT (Ghosh
et al., 2010).
Macroautophagy (hereafter referred to as autophagy) has
been shown to participate in glucose, protein, and, recently, lipid
metabolism (Kovsan et al., 2009). The autophagic process
involves the formation of double membrane autophagosomes
that sequester cytoplasmic contents and subsequently fuse
with lysosomes, thus delivering the autophagic body into the
lysosomal lumen for degradation (Klionsky, 2005). The initiating
event in autophagy is nucleation of the membrane that will
form the autophagosome (Tooze and Yoshimori, 2010), after
which the microtubule-associated protein 1A/1B light chain 3
(LC3) conjugation system acts in membrane elongation and
autophagosome formation (Tanida, 2010). Following autophago-
some fusion with the lysosome, cytosolic components seques-
tered in the autophagosome are degraded by acid proteases
and hydrolases in the autolysosome.
The idea that autophagy is simply a means for bulk degrada-
tion of cytoplasmic constituents is changing as examples of pref-
erential targeting of cargo for autophagic degradation emerge,
revealing the selectivity of the process (Weidberg et al., 2009).
In addition to the forms of selective autophagy previously
described, such as xenophagy (selective delivery of microorgan-
isms to lysosomes), pexophagy (selective peroxisome cargo),
mitophagy, ribophagy, ERphagy, etc., each of which possesses
unique protein requirements (Weidberg et al., 2009), a type of
autophagy describing the selective delivery of LDs for lysosomal
degradation was recently described and has been termed
‘‘lipophagy’’ (Singh et al., 2009a). Here, we report that in athero-
genic pathophysiological conditions (exposure to modified
low-density lipoprotein [LDL]), autophagy is activated in macro-
phages, and this process contributes to intracellular lipid break-
down. Cytoplasmic LD-associated CE delivered to lysosomes
by way of autophagy undergoes lysosomal acid lipase (LAL)-
dependent lipolysis, thereby generating free cholesterol for
efflux to a cholesterol acceptor. Consequently, cholesterol efflux
from lipid-loaded macrophages is dependent upon LD catabo-
lism by autophagy, and the importance of this process in
whole-body RCT is highlighted by the impaired ability of Atg5/
macrophages to clear accumulated 3H-cholesterol in vivo.ell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc. 655
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Lysosomes Contribute to Lipid Breakdown
in Macrophage Foam Cells
Because the internalization of modified LDL is an unregulated
process that leads to foam cell formation (Goldstein et al.,
1979; Shashkin et al., 2005), we used acetylated LDL (AcLDL)
to elevate macrophage intracellular cholesterol levels. Bone
marrow-derived macrophages were incubated with AcLDL for
30 hr, after which the cells were washed and the lipoproteins
were chased during an overnight equilibration. At this time, all
of the AcLDL was degraded and excess cholesterol was stored
as neutral lipids in cytoplasmic LDs (see Figure S1 available on-
line). Whereas oxidized LDL (OxLDL) tends to become trapped
within the endolysosomal compartment (Schmitz and Grandl,
2009), AcLDL is known to be quite rapidly processed in the lyso-
some, and the majority of its associated cholesterol is stored in
cytoplasmic LDs (Brown et al., 1979; Cox et al., 2007; Itabe
et al., 2000; Jerome et al., 1998; Yancey and Jerome, 1998).
Bodipy 493/503 is commonly used to fluorescently stain neutral
lipids (Listenberger and Brown, 2007). To visualize LDs in real
time, neutral lipids were stained with Bodipy and the cells were
observed by confocal microscopy in a 37C heat chamber.
Macrophage LDs could be seen surrounding an unidentified
circular organelle, and over time the formation of a ‘‘ring’’ stained
for neutral lipids could be observed around this unknown organ-
elle (Figure 1A and Movie S1).
Recently, it was suggested that LDs could undergo transient
heterotypic fusion events with bilayered organelles, whereby
lipids transferred from the LDs to the space between the leaflets
of the phospholipid bilayer surrounding the recipient organelle
could subsequently be hydrolyzed and incorporated into the
recipient organelle (Murphy et al., 2008). To investigate whether
such an event was occurring in our cells, LDs were observed in
the presence of LysoTracker Red, which stains acidic organ-
elles. Interestingly, the neutral lipid rings that seem to originate
from LDs overlapped with acidic rings (arrows, Figure 1B and
Movie S2), and even more intriguing, some LDs were entirely
surrounded by acidic rings (asterisks, Figure 1B), suggesting
that they had fused with acidic organelles. To determine whether
the acidic organelle within which LDs could be observed was the
lysosome, we incubated the cells with DQ Red BSA, which
selectively fluoresces in the degradative environment of the
lysosome. Indeed, LDs were observed within lysosomes (arrow-
heads, Figure 1C). The proportion of LD neutral lipids within lyso-
somes was 15% ± 5%. Because of the colocalization between
the macrophage LD coat protein adipophilin and lysosomal-
associated membrane protein 1 (LAMP-1)-positive lysosomes
(Figure 1D), we concluded that the neutral lipid observed within
lysosomes was LD-associated CE, and not simply CE from undi-
gested AcLDL. The frequency at which adipophilin was found
within lysosomes (9% ± 3%) was similar although slightly lower
than that observed for neutral lipids. Together, these observa-
tions led us to postulate that lysosomes may contribute to LD-
associated CE hydrolysis in macrophage foam cells.
While the importance of mobilizing cholesterol from LDs is
acknowledged, it remains a poorly understood process. Many
candidate neutral CE hydrolases have been identified, none of
which has been unambiguously shown to be responsible for all656 Cell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc.CE hydrolytic activity in macrophages; individual contributions
of the various CE hydrolases have yet to be defined (Ghosh
et al., 2010). Paraoxon or E600, which binds irreversibly to the
active site of lipases such as carboxylesterases (Ileperuma
et al., 2007), is commonly used as a general lipase inhibitor
(Wei et al., 2007). To determine the importance of neutral and
potentially acid hydrolases in macrophage CE hydrolysis, we
added paraoxon (to inhibit neutral CE hydrolysis) or chloroquine,
a lysosomotropic agent that interferes with vesicular acidifica-
tion (to inhibit lysosomal CE hydrolysis), during incubation of
lipid-loaded macrophages with lipid-poor apoA-I. Because
macrophage CE undergoes a continual cycle of hydrolysis
and re-esterification (Brown et al., 1980), we included an ACAT
inhibitor during this period to prevent the re-esterification of
hydrolyzed CE. We found that macrophage CE mass increased
in both chloroquine- and paraoxon-treated cells, their com-
pound effect being cumulative (Figure 1E). The independent
inhibition of neutral and lysosomal CE hydrolysis resulted in
a substantial decrease in CE hydrolysis, whereas inhibition of
both pathways abolished CE hydrolysis entirely (Figure 1F).
To evaluate whether lysosomal LD-associated CE hydrolysis
is implicated in mobilization of cholesterol for efflux, macro-
phages were loaded with AcLDL containing 3H-cholesterol,
and efflux of the labeled cholesterol to lipid-poor apoA-I was
measured. AcLDL-derived 3H-cholesterol is esterified in the
ER and accumulates in LDs (Figure S1). The movement of
3H-cholesterol from lipid-loaded macrophages to apoA-I is
unidirectional and is an accurate parameter of the flux of choles-
terol mass out of the cell (Figure S1 and Sankaranarayanan et al.,
2010). Paraoxon diminished but did not abolish cholesterol efflux
(Figure 1G), implying that an additional mechanism for choles-
terol mobilization for efflux in lipid-loaded macrophages exists.
In agreement with a role for lysosomal hydrolysis in regulating
cytoplasmic CE, the addition of chloroquine also resulted in
decreased cholesterol efflux (Figure 1G). Together, these results
point to a role for both neutral and acidic CE hydrolysis in mobi-
lizing cholesterol from cytoplasmic CE stores.
Autophagic Flux Modulates Foam Cell Lipolysis
Having established a role for lysosomal function in LD CE hydro-
lysis and efflux, how LDs became localized within lysosomes
was an enigma, particularly since complete fusion between
monolayered and bilayered organelles is not possible. A timely
report by Singh and colleagues (Singh et al., 2009a), document-
ing the sequestration of LDs by the autophagic machinery and
their subsequent delivery to lysosomes in triglyceride-enriched
hepatocytes, provided a plausible explanation for our own
observations in CE-enriched macrophages. To assess whether
autophagy was involved in LD CE processing in macrophage
foam cells, we first searched for evidence of autophagic vacu-
oles in lipid-loaded macrophages and, if present, whether these
were associated with LDs.
The LC3 conjugation system is essential for autophagy
(Tanida, 2010). Cytosolic LC3 (LC3-I) is modified to its
membrane-bound form (LC3-II), which is located on preautopha-
gosomes and autophagosomes and thus commonly used as an
autophagosomal marker (Kabeya et al., 2000). A direct associa-
tion between LDs and LC3 was observed by immunofluores-
cence (arrows, Figure 2A). In some instances, multiple LC3
Figure 1. LDs Surround Neutral Lipid Rings and Colocalize with Lysosomes; Inhibition of Lysosomal Function Reduces CE Hydrolysis and
Cholesterol Efflux
(A and B) BMDMs were loaded with AcLDL-derived cholesterol for 30 hr, equilibrated overnight in BSA media, and then incubated with media containing Bodipy
(10 mg/mL) with or without LysoTracker Red (50 nM) for 30 min prior to visualization.
(C) Cells were cholesterol loaded as above and then incubated with a BSA conjugate prior to labeling with Bodipy.
(D) Colocalization between the macrophage LD coat protein adipophilin and LAMP-1-positive lysosomes in AcLDL-loaded macrophages.
(E and F) Cellular CE (E) and CE hydrolysis (F) were measured in AcLDL-loaded cells treated with paraoxon or chloroquine for 24 hr in the presence of apoA-I,
with or without ACATi. Variations in CE are expressed as fold change relative to control (E) or as a percent CE hydrolysed in 24 hr (F). ***p < 0.0001, **p < 0.001, or
*p < 0.005 compared to ACATi, and ACATi was compared to control.
(G) BMDMs were loaded with 3H-cholesterol-AcLDL for 30 hr and equilibrated overnight, and efflux to apoA-I was measured for 24 hr in the presence or absence
of paraoxon or chloroquine.
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the LDs (boxed, Figure 2A) that could represent lysosomes or
multivesicular bodies containing significant amounts of neutral
lipids (perhaps multiple LDs). Previously described morpholog-
ical criteria (Singh et al., 2009a) were used to further define LD
sequestration by autophagic vesicles by electron microscopy.CLDs (stars, Figure 2B) were easily recognized as circular elec-
tron-transparent organelles that were not surrounded by the
double membrane characteristic of other organelles. Electron
microscopy of lipid-loaded macrophages revealed double-
membrane vesicles analogous to autophagosomes in and
around LDs (arrows, Figure 2B) and degradative structuresell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc. 657
Figure 2. Autophagy Is Implicated in Cytoplasmic LD Degradation
(A–C) In lipid-loaded BMDMs, direct association of autophagomes with LDs is observed by immunofluorescence (A), electron microscopy (B), and in an isolated
LD fraction (C).
(D) Vinblastine treatment inhibits autophagosome degradation, as shown by elevated LC3-II.
(E) Inhibition of autophagy by vinblastine treatment during cholesterol efflux decreases efflux to apoA-I.
(F) Quantification of LDs containing gold particles (cells immunostained with LC3 are compared to the secondary antibody alone negative control).
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nature of the double membrane vesicles at the LD periphery
was confirmed by LC3 immunogold label (open arrowheads, Fig-
ure 2B). Blind counts revealed that 40% of LDs were associated
with LC3 (Figure 2F).
Another line of evidence for the association of autophago-
somes and LDs was the occurrence of LC3-II protein in the LD
fractions of foam cells (Figure 2C). Chloroquine treatment inhibits
LC3 degradation, and thus there was increased LC3-II in
both the cytoplasmic and LD pools—best seen in 2 and 7 s
exposures, respectively. Finally, we evaluated whether a phar-
macological modulator of autophagy alters cholesterol efflux.
Vinblastine, which inhibits the fusion between autophagosomes658 Cell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc.and lysosomes, leads to the accumulation of autophagosomes
and their associated protein marker, LC3-II (Figure 2D). Inhibition
of autophagy by vinblastine in lipid-loaded macrophages
reduced cholesterol efflux (Figure 2E). Collectively, these results
support a role for autophagy in the degradation of cytoplasmic
LDs.
Activation of the Autophagic Machinery in Response
to Lipid Loading
Because all cytoplasmic CE hydrolysis has previously been
attributed to the action of extralysosomal, neutral CE hydrolases
(Brown et al., 1980; Cheng et al., 2006), we were compelled to
investigate whether the autophagy-dependent mobilization of
Figure 3. Autophagy Is Induced in Re-
sponse to Lipid Loading, and LAL Mediates
LD Catabolism
(A) Chloroquine inhibits cholesterol efflux in
macrophage foam cells, but not in unloaded cells.
(B) Chloroquine has no effect on cholesterol efflux
at an early time point, but impairs cholesterol efflux
upon prolonged inhibition of lysosomal function.
(C) Autophagic flux is induced in lipid-loaded
macrophages.
(D and E) Effect of LAL inhibition on cholesterol
efflux (D) and cellular CE mass (E) in unloaded
versus lipid-loaded macrophages.
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specific to lipid-loaded cells and sensitive to the length of treat-
ment. We found chloroquine to be effective in the attenuation of
cholesterol efflux from lipid-loaded cells, but not in LDL-treated,
unloaded macrophages (Figure 3A). Chloroquine treatment had
no significant effect on AcLDL-loaded cells when included
during a 4 hr cholesterol efflux experiment, as previously re-
ported (Brown et al., 1980), but a significant inhibition could be
seen at 18 hr (Figure 3B). Thus, lysosomal cytosolic CE hydro-
lysis is required for cholesterol efflux in lipid-loaded cells;
LD-associated CE hydrolysis in macrophage foam cells is not
exclusively dependent upon neutral CE hydrolases.
To investigate whether autophagy is specifically induced in
macrophage foam cells, we probed protein samples for LC3
and found LC3-II to be elevated in response to lipid loading (Fig-
ure 3C). To ensure that the rise in LC3-II was not simply due to
defective autophagosome clearance resulting in cellular auto-
phagosome accumulation, chloroquine was added to the mediaCell Metabolism 13, 655–2 hr prior to protein isolation. A further
increase in LC3-II protein upon lysosomal
inhibition was observed, indicative of
a functional autophagic flux in these cells,
as cellular LC3 levels per se are not
a good marker for autophagy (Tanida
et al., 2005). Thus, autophagy is expressly
triggered in macrophages in response to
an expanded cytoplasmic cholesterol
pool.
LAL is the enzyme that hydrolyzes
neutral lipids delivered to lysosomes by
receptor-mediated endocytosis (Gold-
stein et al., 1975). Because the lysosome
population within a cell is comprised of a
heterogeneous pool of lysosomal sub-
groups with distinct roles in autophagy
(Cuervo et al., 1997), and since it has
been proposed that autophagy-compe-
tent lysosomes could utilize Atg15, an
Atg (autophagy-related gene) family
member predicted to hydrolyze neutral
lipids (Kovsan et al., 2009), we next
sought to determine which acid lipase is
implicated in autophagy-mediated LD
CE hydrolysis. We used a potent andspecific LAL inhibitor, compound 13 or 3a2 (Rosenbaum et al.,
2009, 2010), herein referred to as Lalistat 1, to determinewhether
LAL is implicated in LD breakdown in our foam cell model. As
previously shown (Rosenbaum et al., 2009), the administration
of Lalistat 1 during AcLDL loading prevents LD formation
because Lalistat 1 effectively blocks LAL-mediated AcLDL lipid
hydrolysis (Figure S2).
The addition of Lalistat 1 to lipid-loaded cells during choles-
terol efflux reduced efflux and resulted in a concomitant rise in
cellular CE mass (Figures 3D and 3E). To ensure that the Lalistat
1-inhibitable efflux from AcLDL-loaded macrophages indeed
represents LD-associated cholesterol, and not cholesterol
associated with AcLDL trapped in lysosomes, we used an
ACAT inhibitor to prevent LD formation and measured efflux in
the presence of Lalistat 1. We found that in the absence of
LDs, inhibition of LAL had no effect on cholesterol efflux, indi-
cating that the Lalistat 1-inhibitable efflux in AcLDL-loaded
macrophages is LD cholesterol (Figure S2). Together, these667, June 8, 2011 ª2011 Elsevier Inc. 659
Figure 4. Ablation of Autophagy Impairs LD Delivery to Lysosomes for LAL-Mediated CE Hydrolysis in Macrophage Foam Cells
(A) Atg5 deletion in macrophages impairs LC3-I maturation to LC3-II, and autophagy cannot ensue.
(B and C) Cholesterol loading is similar in WT and Atg5/ macrophages, as recorded by mass measurements (B) and 3H-cholesterol uptake (C).
(D) Cholesterol efflux to apoA-I is impaired in Atg5/ lipid-loaded macrophages; LAL inhibition reduces cholesterol efflux in WT, but not Atg5/, macrophages.
+p < 0.0001 relative to WT control, and #p < 0.05 relative to Atg5/ control.
(E) CE hydrolysis in lipid-loadedWT and Atg5/macrophages over 24 hr in the presence of apoA-I, expressed as a fold change relative to theWT control (cellular
CE mass was measured before and after cholesterol efflux, and resulting percent hydrolysis was normalized to that of WT).
(F) Autophagy-deficient macrophages exhibit impaired LD catabolism. Lipid-loaded WT or Atg5/ macrophages were immediately fixed for fluorescence
microscopy after AcLDL loading or after a 24 hr incubation with media containing lipid-poor apoA-I in the presence of an ACAT inhibitor. Neutral lipids were
stained with Nile Red.
(G) AcLDL-derived 3H-cholesterol is esterified to 14C-oleic acid to the same extent in WT and Atg5/macrophages. In the absence of the ACATi, esterification
of the 3H and 14C labels parallels each other and is equivalent inWT and Atg5/ cells. When the ER-resident ACAT is inhibited by ACATi, esterification of both the
3H and 14C labels is abolished.
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loaded cells and mediates the delivery of cytoplasmic LDs to
lysosomes, where LD-associated CE is hydrolyzed by LAL to
liberate cholesterol for efflux.
Impaired LD Catabolism in Atg5–/– Macrophage
Foam Cells
Next, we sought to measure cholesterol efflux in macrophages
isolated from Atg5/ mice as compared to wild-type (WT)
controls. In cells lacking Atg5, the modification of LC3-I to
LC3-II is impaired (Mizushima et al., 2001)—corroborated here
by the complete absence of LC3-II in these cells (Figure 4A)—
and autophagy cannot ensue. Again, autophagosome formation
was induced in macrophages in response to lipid loading (Fig-
ure 4). Autophagosomes are initiated by repression of the
mammalian target of rapamycin (mTOR) or by the class III phos-
phoinositide 3-kinase (PI3K)/Beclin-1 complex. We have thus
far failed to observe changes in Beclin-1 protein levels in
lipid-loaded macrophages (Figure 4A), making mTOR a likely
candidate for modulating autophagy in foam cells, although an
alternative pathway independent of mTOR and class III PI3K/
Beclin-1 for triggering of autophagy has also been described
(Lepine et al., 2010).
Given that autophagy is required for LD genesis and lipid
storage in adipose tissue (Baerga et al., 2009; Singh et al.,
2009b; Zhang et al., 2009), along with additional findings that
the Atg conjugation system is involved in LD formation in hepa-
tocytes and cardiomyocytes (Shibata et al., 2009), we assessed
the ability of autophagy-defective macrophages to accumulate
neutral lipids in LDs when exposed to AcLDL. Neutral lipids in
AcLDL-loaded Atg5/ macrophages effectively accumulated
in LDs, since all cytoplasmic lipid inclusions were surrounded
by adipophilin (Figure 4F, after cholesterol loading). Thus, LD
formation in lipid-loaded Atg5/macrophages occurs normally.
Moreover, the extent of cholesterol loading was comparable in
WT and Atg5/macrophages (Figures 4B and 4C). Importantly,
cholesterol efflux from lipid-loaded Atg5/ macrophages was
significantly reduced as compared to WT macrophages (Fig-
ure 4D), likely due to decreased CE hydrolysis in Atg5/macro-
phages as compared to WT (Figure 4E).
Our hypothesis that autophagy plays a key role in the efflux of
LD cholesterol was further corroborated by microscopic obser-
vations showing that accumulated cytoplasmic LDs dissipate
after incubation with apoA-I in WT, but not in Atg5/ macro-
phages (Figure 4F). Adipophilin, whose levels are directly corre-
lated to cellular LD content, also visibly dissipates in WT cells
after efflux, but not in Atg5/ cells. The observation that Lalistat
1 treatment impairs cholesterol efflux to apoA-I in WT, but not
Atg5/ macrophages (Figure 4D), firmly establishes that
autophagy is the means by which LDs are delivered to LAL for
hydrolysis. The observation that paraoxon is effective at
reducing efflux in both WT and Atg5/macrophages substanti-
ates the idea that CE hydrolysis by neutral CE hydrolases and
autophagy are mutually exclusive pathways. Notably, inhibition
of both pathways nearly abolishes all efflux to apoA-I.(H) Degradation of lipoprotein 3H-cholesteryl oleate occurs at the same rate in WT
containing 3H-cholesteryl oleate in the presence or absence of Lalistat 1 to inhibit
the presence of the ACATi to prevent re-esterification of the liberated 3H-choles
CTo rule out the possibility that the CE accumulation observed
in Atg5/ macrophages is due to enhanced esterification of
cholesterol or decreased lysosomal hydrolysis of lipoprotein
CE in Atg5/ cells compared to WT, we directly measured
both of these parameters in WT and Atg5/ macrophages.
We found that esterification of lipoprotein 3H-cholesterol to
14C-oleic acid did not differ between WT and Atg5/ macro-
phages (Figure 4G). Consistent with the well-established role
for ACAT in mediating cholesterol esterification in the ER, the
esterification of both radiolabels was abolished in the presence
of the ACAT inhibitor. Degradation of lipoprotein-associated
3H-cholesteryl oleate was equivalent in WT and Atg5/ macro-
phages (Figure 4H), indicating that the observed decrease in
cholesterol efflux from Atg5/ cells does not result from
augmented lipoprotein CE retention in Atg5/ cells as com-
pared toWT.Most importantly, these results clearly demonstrate
that AcLDL CE is processed very rapidly in lysosomes as
compared to OxLDL CE. During this experiment, only 10% of
AcLDL CE remained after a 30 hr incubation. This small amount
of residual AcLDL CE minimally decreased during an O/N chase
(to 7%–8%) and is likely to represent a background amount that
could not account for the relative decrease in cholesterol efflux
observed in Atg5/ cells.
Autophagy Is Induced by Atherogenic Lipoproteins
and by Cholesterol Loading In Vivo
To further characterize the physiological relevance of this
pathway, we tested whether autophagy was also induced in
macrophages incubated with pathophysiological forms of
modified LDL, such as OxLDL and aggregated LDL (AgLDL),
andwith very low density lipoprotein (VLDL). We found that, simi-
larly to AcLDL, incubation of macrophages with AgLDL or VLDL
resulted in the accumulation of cytoplasmic neutral lipids,
whereas mildly OxLDL generated few LDs (consistent with its
documented lysosomal retention) (Figure 5A). Importantly, all
of these lipoproteins increased autophagic flux in macrophages
(Figure 5B), and autophagy depletion in these cells resulted in
diminished cholesterol efflux to apoA-I (Figure 5C).
Efflux assays to lipid-free apoA-I and HDL probe two distinct
pathways of unidirectional and bidirectional cholesterol trans-
fers, respectively (Rothblat and Phillips, 2010). Here, we as-
sessed whether both of these efflux pathways were dependent
on autophagy. Interestingly, whereas virtually all efflux to
apoA-I was attributable to autophagy in AcLDL-loaded cells,
approximately 30% of HDL-mediated efflux was dependent on
this process (Figure 5D). It should be noted that the efflux rates
measured here are similar to those in the literature, where efflux
to HDL is greater than that to apoA-I (Wang et al., 2000; Zhang
et al., 2003). To assess the proportion of autophagy-mediated
efflux that derives from LD cholesterol in cells incubated with
apoA-I or HDL, we performed efflux experiments in the presence
of an ACAT inhibitor. ACATi was included for the entire duration
of these experiments, preventing cholesterol esterification
and LD biogenesis (Figure S1), which results in endosomal
and lysosomal cholesterol accumulation (Dove et al., 2005).and Atg5/macrophages. Macrophages were loaded with AcLDL or OxLDL
LAL, followed by an O/N equilibration or not. All experiments were performed in
terol.
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Figure 5. Enhanced Autophagy in Response to Various Atherogenic Lipoproteins and in Peritoneal Macrophages from Hypercholesterol-
emic Mice
(A) LD genesis in bone marrow-derived macrophages exposed to AgLDL, VLDL, and OxLDL.
(B) Elevated autophagic flux in response to atherogenic lipoproteins.
(C) Impaired efflux to apoA-I in atg5/ macrophages loaded with AgLDL, VLDL, and OxLDL.
(D) Atg5 ablation reduces cholesterol efflux to HDL in AcLDL-loaded macrophages.
(E and F) Efflux to apoA-I (E) and HDL (F) in WT and Atg5/ macrophages with (control) or without (ACATi) cytoplasmic LDs.
(C–F) +++p < 0.0001 or +p < 0.05 relative to WT control, and ##p < 0.001 or #p < 0.05 for ACATi-treated WT cells relative to WT control, andAAp < 0.001
orAp < 0.05 for ACATi-treated Atg5/ cells relative to ACATi-treated WT cells.
(G) Autophagy mediates cholesterol efflux in peritoneal macrophages.
(H) Peritoneal macrophages isolated from hypercholesterolemic apoe/ mice contain more LDs than their WT counterparts.
(I) Autophagy levels are elevated in peritoneal macrophages lipid loaded in vivo.
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apoA-I quite significantly (60% decrease), whereas efflux to
HDL was slightly increased (Figures 5E and 5F), indicating that
the major source of cholesterol for apoA-I-mediated efflux is
the LD. Additionally, we found that lack of autophagy reduced
cholesterol efflux even in the absence of LDs, suggesting
a role for this pathway in enhancing efflux of lysosomal choles-662 Cell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc.terol independently of its ability to transfer LD CE to these
organelles for LAL-mediated hydrolysis.
We next assessed whether our findings also apply to perito-
neal macrophages. Similar to bone marrow-derived macro-
phages, autophagy was induced in peritoneal macrophages
upon AcLDL loading, and Atg5 deficiency reduced cholesterol
efflux to apoA-I and HDL in these cells (Figure 5G). Moreover,
Figure 6. Macrophage-Specific Deletion of Atg5 Reduces RCT In Vivo
(A) 3H-tracer in plasma at 24 and 48 hr postinjection.
(B) 3H-tracer in livers at 48 hr postinjection.
(C) 3H-tracer in gallbladders at 48 hr postinjection.
(D) 3H-tracer in feces at 48 hr postinjection.
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phages isolated from hypercholesterolemic apoe/ mice as
compared to WT cells (Figure 5I). Cellular LDs were more
numerous in the cytoplasm of apoe/ macrophages as com-
pared to control mice (Figure 5H), confirming the in vivo loading
of these macrophages. Thus, our findings in macrophages lipid
loaded in vitro appear generalizable to in vivo macrophage-
loading conditions.
Lipophagy Contributes to RCT In Vivo
Because the mobilization of cholesterol from LDs is the first step
in the RCT pathway, defined as the flux of cholesterol from
macrophages in peripheral tissues to the liver for excretion, we
reasoned that impaired efflux from autophagy-deficient macro-
phages would result in ineffective whole-body clearance of
accumulated macrophage cholesterol. To measure RCT
in vivo, we used a method developed to quantify 3H-cholesterol
movement from macrophages into plasma, liver, gallbladder,
and feces (Wang et al., 2007; Zhang et al., 2003) over a 2 day
period. Following the injection of WT or Atg5/ macrophages
loaded with AcLDL-derived 3H-cholesterol into C57BL/6 mice,
we found that the clearance of the macrophage 3H-tracer was
significantly reduced in mice receiving Atg5/ macrophages
as compared to WT macrophages (Figures 6A–6D). Thus,
macrophage-specific impairment of autophagy is clearly
detrimental to in vivo RCT, a process that plays a critical athero-
protective role.CDISCUSSION
Here we demonstrate an important role for lysosomes in cyto-
plasmic CE hydrolysis in macrophage foam cells. Furthermore,
we demonstrate that LDs are delivered to lysosomes via autoph-
agy, where LAL acts to hydrolyze LD-associated CE to generate
free cholesterol for efflux, a process that is specifically induced
upon cholesterol loading in macrophages. Lysosomal lipolytic
activity has been well studied, but it is only now realized that
the source of lipids undergoing lipolysis in this compartment is
not limited to extracellular lipoprotein-associated lipids reaching
lysosomes via endocytosis but also extends to cytoplasmic LDs
(Rodriguez-Navarro and Cuervo, 2010). CE-enriched macro-
phage foam cells have been shown (puzzlingly) to divert some
of their cytoplasmic neutral lipids to lysosomes for hydrolysis
(Avart et al., 1999). We corroborate and extend these earlier
observations: sequestration of LDs by autophagosomes delivers
LD CE to lysosomes, where it undergoes LAL-mediated hydro-
lysis to generate free cholesterol for efflux (Figure 7).
There aremanymodels for foam cell formation in vitro, such as
incubation of macrophages with AcLDL (a model modified LDL)
or other atherogenic lipoproteins such as OxLDL, AgLDL, and
VLDL (all of which are formed and may accumulate in patholog-
ical conditions in vivo). The AcLDL model has been extensively
characterized since the late 1970s (Basu et al., 1976; Goldstein
et al., 1979), and the cytoplasmic accumulation of AcLDL-
derived cholesterol as CE in LDs is well documented (Brownell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc. 663
Figure 7. Model of Autophagy in LD-Associated CE Hydrolysis in Macrophage Foam Cells
(A) Cholesterol homeostasis in ‘‘normal,’’ unloadedmacrophages; a model for CE hydrolysis that mainly involves the action of neutral CE hydrolases is presented.
(B) Autophagy is induced in early macrophage foam cells, and delivery of LDs to lysosomes enhances LD-associated CE hydrolysis and cholesterol efflux.
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1998; Yancey and Jerome, 1998). Multiple pieces of evidence
support the premise that LDs are processed in lysosomes in
the AcLDL-loaded macrophages used in our study. First, we
could not detect any undigested AcLDL in lysosomes, and all
of the Bodipy- or Nile Red-stained neutral lipidswere surrounded
by the LD coat protein, adipophilin (Figure S1). Also, adipophilin
itself was localized to lysosomes (Figure 1). Furthermore, using
an ACAT inhibitor during AcLDL uptake to prevent cholesterol
esterification and the formation of LDs (Figure S1 confirms the
lack of esterification and the lack of cytoplasmic LDs under these
conditions), we found that the Lalistat 1-inhibitable efflux was
abolished in the absence of LDs (Figure S2). In addition, there
was diminished dissipation of adipophilin-coated neutral lipids
after a 24 hr incubation of AcLDL-loaded macrophages with
apoA-I in Atg5/ macrophages relative to WT cells (Figure 4F).
Moreover, efflux to apoA-I, which was nearly abolished in
Atg5/ macrophages (Figure 5E), was primarily dependent on
LDs as a cholesterol source (Figure 5E, there is a 60% reduction
in efflux to apoA-I in WT cells loaded with AcLDL in the presence
of the ACATi as compared to WT cells loaded without ACATi in
which LDs form). Finally, we show that AcLDL CE is processed
very rapidly in lysosomes, and that lipoprotein-associated CE
hydrolysis was equivalent in WT and Atg5/macrophages (Fig-
ure 4H). Thus, the decrease in cholesterol efflux from Atg5/664 Cell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc.cells could not result from enhanced lipoprotein CE retention in
these cells as compared to WT. In any case, residual lysosomal
CE after AcLDL loading is quite minimal and could not account
for the decrease in efflux observed in Atg5/ macrophages.
While cytosolic LDs are the site for CE accumulation in macro-
phages incubated with AcLDL, other modified lipoproteins
(oxLDL, agLDL, enzymatically modified LDL) show some degree
of accumulation in endolysosomal structures (Griffin et al., 2005;
Schmitz and Grandl, 2009). Macrophage foam cells in human
atherosclerotic lesions also display similar lipid accumulation.
In early lesions, macrophage foam cells accumulate mostly
cytosolic LDs (Stary et al., 1994), whereas in foam cells of
advanced atherosclerotic plaques much of the cholesterol is
trapped in lysosomes (Jerome, 2006). The evidence that autoph-
agy is induced with lipid loading and actively mobilizes LD CE
indicates that autophagy and LAL may be particularly relevant
to the reversal of early lesions. Our results also support a possible
role in the regression of advanced lesions. As seen from Fig-
ure 5E, even in the absence of any cytoplasmic LDs, there is
an autophagy-attributable efflux to apoA-I.
Here, we clearly establish that autophagy-mediated efflux is
closely linked to the ATP-binding cassette (ABC) transporter
ABCA1, which itself is linked to the endosomal/lysosomal
cholesterol pools. In the absence of LDs and autophagy, efflux
to apoA-I is nearly completely abolished, whereas this is not
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Autophagy Regulates Macrophage Cholesterol Effluxthe case for efflux to HDL (Figures 5E and 5F). This implies that
autophagy-mediated efflux is primarily ABCA1 dependent, since
efflux to lipid-poor apoA-I is completely dependent on ABCA1,
whereas this transporter contributes to a small proportion of
HDL-mediated efflux (Wang et al., 2000). Whereas ABCA1medi-
ates a unidirectional transport, mostly to apoA-I (Wang et al.,
2000), HDL-mediated efflux is a bidirectional, diffusional process
that involves multiple transporters (Rothblat and Phillips, 2010)
and represents a complex pathway for which the contribution
of autophagy remains to be studied in greater detail. Macro-
phage ABCA1 is responsible for approximately 50% of total
RCT in vivo (Wang et al., 2007), but its contribution to efflux to
HDL is low in vitro (Wang et al., 2000). In agreement with these
findings, we observed a modest decrease in efflux to HDL in
Atg5/ macrophages in vitro (Figures 5D and 5F) and a more
pronounced effect of macrophage-specific autophagy deletion
on excretion of macrophage 3H-cholesterol in vivo (Figure 6).
Autophagy is markedly elevated in macrophages in response
to lipid loading (Figure 3). Fittingly, under lipid-loaded conditions,
apoA-I/ABCA1 retroendocytosis (a process by which apoA-I
acquires lipid from late endosomal/lysosomal compartments)
contributes to efficient cholesterol efflux, whereas in the
absence of cholesterol loading, lipidation of apoA-I occurs
primarily at the plasmamembrane (Azuma et al., 2009). Addition-
ally, ABCA1 expression is increased in response to cholesterol
loading, both transcriptionally via the liver X receptor (LXR)
(Beaven and Tontonoz, 2006) and posttranscriptionally by miR-
33 (Rayner et al., 2010). Using an LXR activator (T0901317) to
maximally stimulate ABCA1 activity dramatically enhances
cholesterol efflux to apoA-I; in Lalistat 1-treated and Atg5/
macrophages, however, T0901317 fails to increase efflux to
apoA-I, given that cholesterol delivery to ABCA1 under these
conditions is seemingly limiting (Figure S3).
Our observation that the expansion of intracellular cholesterol
pools triggers autophagy seems contradictory to previous
reports linking the depletion of cellular cholesterol levels to
autophagy induction in fibroblasts (Cheng et al., 2006) and in
hepatocytes (Seo et al., 2011). However, increased LD delivery
to lysosomes has been shown to occur in response to starvation
aswell as triglyceride loading in hepatocytes (Singh et al., 2009a).
Importantly, the prolonged presence of lipogenic stimuli ulti-
mately results in inhibition of autophagosome clearance by lyso-
somes. Whereas a moderate cholesterol increase was shown to
increase autophagic flow, the fusogenic ability of the autophagic/
lysosomal compartments is attenuated in conditions of chronic
lipid exposure (Koga et al., 2010). It will be interesting to deter-
mine whether autophagy becomes defective in macrophages
derived from advanced atherosclerotic lesions as compared to
early foam cells. Impairment of autophagy-mediated cholesterol
clearance in advanced foam cells would be predicted to exacer-
bate lipid accumulation in these lesions, given that RCT from
Atg5/macrophages is significantly reduced in vivo (Figure 6).
In summary, we demonstrate an important role for autophagy
in cholesterol efflux from macrophage foam cells (Figure 7). We
demonstrate that this pathway is important for macrophage LD
clearance in primary bone marrow-derived and peritoneal
macrophages. Autophagy-dependent macrophage cholesterol
efflux is an ABCA1-mediated process that is enhanced by the
uptake of various atherogenic lipoproteins such as AcLDL,COxLDL, AgLDL, and VLDL in vitro. In addition, we report that
the autophagy pathway is induced in peritoneal macrophages
loaded in vivo. Based on the finding that macrophage-specific
autophagy deficiency is detrimental to RCT, impairment of
macrophage autophagy would be expected to promote athero-
sclerotic lipid accumulation. Activators of autophagy, which
trigger autophagy via mTOR inhibition, are emerging as prom-
ising agents to treat coronary heart disease (Jia and Hui, 2009).
The systemic administration of mTOR inhibitors has been shown
to prevent development of atherosclerosis, attenuate plaque
progression, and reduce cholesterol content in the aortic arch
in atherogenic mouse models (Basso et al., 2003; Mueller
et al., 2008; Pakala et al., 2005). Although further studies are
required to establish a correlation between the regulation of
autophagy in macrophages and atherosclerosis, our results
suggest that the controlled stimulation of autophagy may
provide therapeutic potential to enhance macrophage choles-
terol efflux and promote RCT.
EXPERIMENTAL PROCEDURES
Cell Culture
Bone marrow cells were flushed from the femurs of C57BL/6 mice or from
Atg5//LDLR/ and LDLR/ mice on a C57BL/6 background and differen-
tiated into macrophages by incubation in L929-conditioned media for 7 days.
Peritoneal macrophages from Atg5//LDLR/ and LDLR/ were harvested
4 days after i.p. injection of methyl-BSA in mice previously immunized with this
antigen. For in vivo macrophage cholesterol loading, apoe/ or WT mice on
a C57BL/6 background were placed on a Western diet for 2 weeks, and peri-
toneal macrophages were harvested 3 days after thioglycolate injection.
Lipoprotein Preparation
HDL, VLDL, and LDL were isolated by sequential density ultracentrifugation.
LDL was acetylated by repetitive additions of acetic anhydride, aggregated
by vortexing, or oxidized by incubation with CuSO4 for 24 hr.
Cholesterol Efflux
Macrophages were incubated for 30 hr in media containing 50 mg/mL of lipo-
proteins that were preincubated with 3H-cholesterol (5 mCi/mL). Cells were
washed and equilibrated overnight in 2 mg/mL BSA media, and cholesterol
efflux was determined in the presence or absence of human recombinant
apoA-I (50 mg/mL) or HDL (50 mg/mL) in serum-free media with the indicated
reagent (paraoxon 100 mM, chloroquine 30 mM, vinblastine 30 mM, bafilomycin
10 nM, ACATi 10 mg/mL, Lalistat 1 10 mM) for 18–24 hr (unless otherwise
specified). Efflux is expressed as a percentage of 3H-cholesterol in medium/
(3H-cholesterol in medium+3H-cholesterol in cells) 3 100%. Efflux to apoA-I
or HDL was calculated by subtracting effluxes of the wells without apoA-I or
HDL from those containing apoA-I or HDL.
In Vivo RCT Studies
Macrophage RCT experiments were carried out similarly to that previously
described (Wang et al., 2007). Macrophages from WT or Atg5/ mice were
loaded with 3H-cholesterol-AcLDL as described above for cholesterol
effluxes, and 200 mL of cell preparations (5 3 106 cells containing 2 3
106CPM) were injected subfascially in the lumbar region of C57BL/6 mice.
Blood was collected at 24 hr via the saphenous vein and at 48 hr via cardiac
puncture of anesthetized mice. Plasma was used for liquid scintillation
counting. At 48 hr, gallbladders were emptied, and livers were removed for
scintillation counting. Feces were collected over a 48 hr period, and total feces
radioactivity (of equivalent wet weight) was measured. All 3H-tracer measure-
ments are expressed relative to the injected amount.
Lipid Measurements
The Biovision Cholesterol Quantitation Kit was used to determine cellularmass
of cholesterol and CEs. Variations in CE are expressed as percent hydrolysis orell Metabolism 13, 655–667, June 8, 2011 ª2011 Elsevier Inc. 665
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(CEi – CEf)/(CEi)*100, where CEi represents the CE mass immediately after
AcLDL loading, and CEf represents the CEmass after the cells were incubated
for 24 hr with apoA-I; fold change = (% hydrolysis sample/% hydrolysis
control).
CE Quantification by TLC
Total lipids were extracted and separated by thin-layer chromatography (TLC)
using a nonpolar solvent system for separation of cholesterol and CE. The
bands corresponding to cholesterol and CE were excised and counted for
radioactivity.
3H-Cholesterol and 14C-Oleic Acid Esterification
Macrophages were incubated with 3H-cholesterol-AcLDL and 0.1 mM sodium
14C-oleate-albumin complex for 30 hr, in the presence or absence of ACATi.
The 3H and 14C labels were quantified in the CE fraction after TLC.
Western Blotting
Cells were lysed in Laemmli sample buffer (Bio-Rad). Total protein samples
were electrophoresed on precast 4%–20% or 18% SDS-polyacrylamide
gels (Invitrogen) and transferred to nitrocellulose or PVDF membranes at
125V for 2 hr. Membranes were probed with the indicated antibodies, which
were detected using HRP-based chemiluminescence.
Lipid Droplet Isolation
LDs were isolated from AcLDL-loaded macrophages by density gradient
centrifugation, and whole LD fractions were used for SDS-PAGE.
Fluorescence Microscopy
Neutral lipids were stained using Bodipy 493/503 or Nile Red. For live cell
imaging, AcLDL-loaded macrophages were incubated with Bodipy (10 mg/mL)
with or without LysoTracker Red (50 nM) for 30 min prior to visualization,
or with 10 mg/mL of the BSA conjugate 4 hr prior to labeling with Bodipy. For
immunofluorescence, cells were fixed in 4% PFA, blocked/permeabilized in
2.5%BSA/0.1%Triton X-100, and stainedwith the indicatedprimary antibodies
for 1 hr at 37C. Fluorophore-conjugated secondary antibodies were incubated
in the presence of Nile Red (50 ng/mL) to stain neutral lipids. Confocal images
andmovieswereobtainedusing anOlympus IX80FV1000confocalmicroscope
with appropriate lasers.
Electron Microscopy
AcLDL-loaded macrophages were fixed in 1.6% glutaraldehyde prior to post-
fixation in osmium tetroxide and uranyl acetate en bloc staining. Samples were
processed and embedded in Spurr epoxy resin, thin sectioned, and counter-
stained with lead citrate. Digital images were obtained with a JEOL 1230
TEM at 60 kV adapted with a 2000 3 2000 pixel bottom-mount CCD digital
camera and AMT software.
LC3 Immunogold Labeling
A pre-embedding method followed by silver enhancement was used for
immunoelectron microscopy. AcLDL-loaded macrophages were fixed in 4%
paraformaldehyde and 0.1%glutaraldehyde in PBS. Cells were permeabilized,
blocked, and immunolabeled with anti-LC3 and incubated with anti-rabbit IgG
conjugated to colloidal gold (1.4 nm diameter). Cells were postfixed with 1%
glutaraldehyde, and the gold was intensified using the HQ Silver Enhancement
Kit (Nanoprobes). Cells were dehydrated with a graded series of ethanol,
embedded, counterstained, and imaged.
Statistical Analysis
All presented values are mean ± SEM. Statistical significance of the differ-
ences between groups was determined using the GraphPad InStat software.
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